Cytotoxicity of B72.3XOKT3 bispecific antibody recognizing human colon cancer

Journal of Surgical Research

Volumn 61, Issue 1, 1996, Pages 134-138

  Shpitz, Baruch ^a   Stern, Hartley ^a   Sandhu, Jas S ^b   Reilley, Raymond M ^c   Tropak, Michael B ^b   Jansz, Gwen ^b   Xu, Jennis ^b   Gallinger, Steven ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b Div of Molec Immunol and Neurbio   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; OKT 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CANCER GROWTH; CARCINOMA CELL; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 0030040898     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1996.0093     Document Type: Article

References (25)

1. Milstein, C., and Cuello, A. C. Hybrid hybridomas and the production of bi-specific monoclonal antibodies. Immunol. Today 5: 299, 1984.
2. Songisivillai, S., and Lachmann, P. Bispecific antibody: a tool for diagnosis and treatment of disease. Clin. Exp. Immunol. 79: 315, 1990.
3. Nolan, O., and O'Kennedy, R. Bifunctional antibodies: concept, production and application. Biochim. Biophys. Acta. 1040: 1, 1990.
4. Nelson, H. Targeted cellular immunotherapy with bifunctional antibodies. Cancer Cells 3: 163, 1991.
5. Fanger, M. W., Morganelli, P. M., and Guyre, P. M. Bispecific antibodies. Crit. Rev. Immunol. 12: 101, 1992.
6. Weiner, L. M., Holmes, M., Richeson, A., Godwin, A., Adams, G. P., Hsieh-Ma, S. T., Ring, D. B., and Alpaugh, K. R. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J. Immunol. 151: 2877, 1993.
7. Garcia de Palazzo, I., Holmes, M., Gercel-Taylor, C., and Weiner, L. M. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16. Cancer Res. 52: 5713, 1992.
8. 2 antibody for the delivery of saporin in the treatment of lymphoma. J. Immunol. 141: 3622, 1988.
9. Nelson, H., Ramsey, P. S., McKean, D. J., Dozois, R. R., and Donohue, J. H. Anti-tumor X anti-lymphocyte heteroconjugates augment colon tumor cell lysis in vitro and prevent tumor growth in vivo. Dis. Colon Rectum 34: 140, 1991.
10. Lanzavecchia, A., and Scheidegger, D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur. J. Immunol. 17: 105, 1987.
11. Jung, G., Ledbetter, J. A., and Muller-Eberhard, H. J. Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc. Natl. Acad. Sci USA 84: 4611, 1987.
12. Gilliland, L. K., Clark, M. R., and Waldmann, H. Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells. Proc. Natl. Acad. Sci. USA 85: 7719, 1988.
13. Barr, I. G., Miescher, S., von Fliedner, V., Bucheger, F., Barras, C., Lanzavecchia, A., Mach, J. P., and Carrel, S. In vivo localization of a bispecific antibody which targets human T lymphocytes to lyse human colon cancer cells. Int. J. Cancer 43: 501, 1989.
14. Garrido, M. A., Perez, P., Titus, J. A., Valdayo, M. J., Winkler, D. F., Barbieri, S. A., Wunderlich, J. R., and Segal, D. Targeted cytotoxic cells in human peripheral blood lymphocytes. J. Immunol. 144: 2891, 1990.
15. Demanet, C., Brissink, J., van Mechelen, M., Leo, O., and Thielemans, K. Treatment of murine B-cell lymphoma with bi-specific monoclonal antibodies (anti-idiotype x anti-CD3). J. Immunol. 147: 1091, 1991.
16. Weiner G., and Hillstrom J. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J. Immunol. 147: 4035, 1991.
17. Qian, J.-H., Titus, J. A., Andrew, S. M., Mezzanzanica, D., Garrido, M. A., Wunderlich, J. R., and Segal, D. M. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J. Immunol. 146: 3250, 1991.
18. Garrido, M. A., Valdayo, M. J., Winkler, D. F., Titus, J. A., Hecht, T. T., Perez, P., Segal, D. M., and Wunderlich, J. R. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice. Cancer Res. 50: 4227, 1990.
19. Beun, G. D., Gorter, A., Nooyen, Y., van de Velde, C., and Fleuren, G. J. T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. J. Immunol. 150: 2305, 1993.
20. Link, B. K., and Weiner, G. Production and characterization of a bispecific IgG capable of inducing T-cell-mediated lysis of malignant B cells. Blood 81: 3343, 1993.
21. Bohlen, H., Manzke, O., Patel, B., Moldenhauer, G., Dorken, B., von Fliedner, V., and Tesch, H. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res. 53: 4310, 1993.
22. Gold, D., and Mattes, M. Monoclonal antibody B72.3 reacts with core region structure of O-linked carbohydrate. Tumor Biol. 9: 137, 1988.
23. Ngai, W., and Railey, R. Simple method to determine immunoreactivity of radiolabeled monoclonal antibody to the TAG-72 antigen. Appl. Radiat. Isot. 44: 1193, 1994.
24. Oliver, L. T. D., and Nouri, A. T cell immune responces to cancer in humans and its relevance for immunodiagnosis and therapy. Cancer Surv. 12: 173, 1991.
25. Roosnek, E., and Lanzavecchia, A. Triggering T cells by otherwise inert hybrid anti-CD3/antitumor requires encounter with the specific target cell. J. Exp. Med. 170: 297, 1989.